Exclusive: The quiet strategy pharma giants use to fend off generics

Also: Senate IVF bill fails again as Democrats pressure GOP on reproductive health

September 18, 2024 Check out STAT+

Sponsored By

Mike Reddy for STAT STAT+ | Inside the quiet strategy pharma giants are using to fend off generics and drive up the cost of medicines FDA Orange Book shows spike in use codes from 0.7 per drug in 2001 to 9.9 today. Analysts say the codes can hamper effort to bring new generic drugs to market. By Ed Silverman and Michael Nolan STAT+ | Roivant strikes another deal, selling dermatology spinoff to Organon in deal worth $1.2 billion CEO Matt Gline has been on a dealmaking spree over the last year, starting off with his sale of a drug to Roche for $7.1 billion upfront last year. By Allison DeAngelis Senate IVF bill fails again as Democrats pressure GOP on reproductive health Democrats are pursuing new attack lines ahead of an election that many see as a referendum on reproductive rights. By Sarah Owermohle NIH/NCI Center for Cancer Research STAT+ | Biotech feud over the multibillion-dollar cancer blood test market spills onto social media Guardant Health co-CEO offers $1 million bet to Exact Sciences CEO that early results of new colon cancer test won't hold up in larger trial By Jonathan Wosen Year-long fallout over retracted trans youth paper highlights new research era A Nature journal published, then retracted, a study surveying parents of trans youth, setting off events that led one editor to resign. By Anil Oza Vance's confusing health insurance remarks give Democrats a new attack line Democrats are characterizing the Trump-Vance ticket as being against a popular health insurance protection. By John Wilkerson and Sarah Owermohle Cliff Hawkins/Getty Images STAT+ | Hospital giant Ascension recorded about $1.3 billion in losses from its cyberattack The cyberattack was a major setback for Ascension's efforts to improve the health system's financial performance. By Bob Herman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser